Agree with the last sentence. RPRX likes to tilt at windmills related to the medical community's blithe disregard for the complexity of endocrine control loops and what that means about treatment. Particularly in the case of Androxal, without some strong clinical benefit (other than fertility which, somewhat oddly, no one cares about). The RPRX fibroids drug at least had a strong clinical benefit even while it had quixotic aspects.
BTW - Podolski sounded close to outright combative in the cc about the latest results. Large risk he isn't hearing what the medical community or the FDA is saying. (This isn't to say that the medical community or the FDA is technically or morally correct - but it is dangerous indeed to ignore either.)
BTW2 - Apparently there is a mid-Sept AdComm on the topic of testosterone replacement. Should be interesting, although difficult to see how any outcome there would benefit RPRX - because right or wrong if T therapy gets hammered then it is likely that all T-raisers will get hammered.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.